Verrica Pharmaceuticals Inc. VRCA
Regular-session close
Pre-market · Nov 20, 4:05 AM ET
- YTD
- -65.28%
- 1 year
- -28.23%
- Market cap
- 49.56M
- Revenue (ttm)
- 9.21M
- EPS (ttm)
- -2.30
- Shares out
- 90.56M
- Forward P/E
- -1.19
- YTD return
- -65.28%
- 1-year return
- -28.23%
- 50-day average
- 1.12
- 200-day average
- 4.58
- Volume
- 77.98K
- Avg volume
- 68.97K
- Open
- 2.95
- Previous close
- 2.86
- Day's range
- 2.78 – 3.18
- 52-week range
- 2.77 – 9.82
- Beta
- 1.46
- Analysts
- Buy
- Price target
- 6.33 (+119.5%)
Key statistics
- Enterprise value
- 55.81M
- Price / sales
- 6.92
- Free cash flow
- -31.81M
- Total cash
- 22.96M
- Total debt
- 47.11M
- Return on equity
- -2059.89%
- Short % of float
- 4.54%
Fundamental scorecard
6 of 25 checks passed on VRCA’s reported financials
6of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.37 | -0.49 | -0.12 | -32.43% |
| Aug 14, 2024 | Jun 1, 2024 | -0.43 | -0.31 | +0.12 | +27.91% |
| Aug 14, 2024 | Jun 1, 2024 | -0.43 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.54 | -0.38 | +0.16 | +29.63% |
| May 13, 2024 | Mar 1, 2024 | -0.54 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.47 | -0.48 | -0.01 | -2.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Needham | reit | Hold | Hold |
| Nov 6, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 5, 2024 | Needham | reit | — | Hold |
| Nov 5, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Oct 21, 2024 | TD Cowen | main | Buy | Buy |
| Oct 4, 2024 | RBC Capital | main | Outperform | Outperform |
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- verrica.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on VRCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONACCORSO JOE | Officer | Sale | Aug 26, 2024 | 73,114 |
| GOLDENBERG GARY | Officer | Sale | Aug 26, 2024 | 94,261 |
| HAYES CHRISTOPHER G | Officer | Sale | Aug 26, 2024 | 105,773 |
| KIRBY JOHN J. | Chief Financial Officer | Stock Award(Grant) | Nov 5, 2024 | 54,267 |
| KOHLER TERRY | Chief Financial Officer | Sale | Aug 26, 2024 | 44,697 |
| MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Nov 25, 2024 | 38,060,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 15.57% | 7,099,182 | 4.99M | Sep 29, 2024 |
| Vanguard Group Inc | 2.82% | 1,286,600 | 905.12K | Sep 29, 2024 |
| Blackrock Inc. | 2.38% | 1,085,439 | 763.61K | Sep 29, 2024 |
| FMR, LLC | 1.39% | 634,310 | 446.24K | Sep 29, 2024 |
| State Street Corporation | 1.12% | 512,821 | 360.77K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.00% | 455,480 | 320.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.79% | 815,893 | 573.98K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.19% | 540,966 | 380.57K | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.14% | 517,629 | 364.15K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.63% | 289,249 | 203.49K | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.44% | 200,000 | 140.70K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.43% | 196,507 | 138.24K | Aug 30, 2024 |
